XOMA Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'XOMA Corporation - Product Pipeline Review - 2016', provides an overview of the XOMA Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by XOMA Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of XOMA Corporation - The report provides overview of XOMA Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses XOMA Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features XOMA Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate XOMA Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for XOMA Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding XOMA Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 XOMA Corporation Snapshot 5 XOMA Corporation Overview 5 Key Information 5 Key Facts 6 XOMA Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 XOMA Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 XOMA Corporation - Pipeline Products Glance 13 XOMA Corporation - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 XOMA Corporation - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 XOMA Corporation - Drug Profiles 17 XOMA-213 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 XOMA-358 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibodies for Undisclosed Disease 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibodies to Antagonize Parathyroid Hormone 1 Receptor for Hyperparathyroidism and Malignancy Induced Hypercalcemia 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 XMet-A 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 XOMA-129 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 XOMA-3-BB 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Antibody to Modulate GPCR 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 XOMA Corporation - Pipeline Analysis 27 XOMA Corporation - Pipeline Products by Target 27 XOMA Corporation - Pipeline Products by Route of Administration 28 XOMA Corporation - Pipeline Products by Molecule Type 29 XOMA Corporation - Pipeline Products by Mechanism of Action 30 XOMA Corporation - Recent Pipeline Updates 31 XOMA Corporation - Dormant Projects 34 XOMA Corporation - Discontinued Pipeline Products 35 Discontinued Pipeline Product Profiles 35 gevokizumab 35 XOMA Corporation - Company Statement 36 XOMA Corporation - Locations And Subsidiaries 39 Head Office 39 Other Locations & Subsidiaries 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
XOMA Corporation, Key Information 5 XOMA Corporation, Key Facts 6 XOMA Corporation - Pipeline by Indication, 2016 8 XOMA Corporation - Pipeline by Stage of Development, 2016 9 XOMA Corporation - Monotherapy Products in Pipeline, 2016 10 XOMA Corporation - Out-Licensed Products in Pipeline, 2016 11 XOMA Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 12 XOMA Corporation - Phase II, 2016 13 XOMA Corporation - Phase I, 2016 14 XOMA Corporation - Preclinical, 2016 15 XOMA Corporation - Discovery, 2016 16 XOMA Corporation - Pipeline by Target, 2016 27 XOMA Corporation - Pipeline by Route of Administration, 2016 28 XOMA Corporation - Pipeline by Molecule Type, 2016 29 XOMA Corporation - Pipeline Products by Mechanism of Action, 2016 30 XOMA Corporation - Recent Pipeline Updates, 2016 31 XOMA Corporation - Dormant Developmental Projects,2016 34 XOMA Corporation - Discontinued Pipeline Products, 2016 35 XOMA Corporation, Subsidiaries 39
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.